vs
Fulgent Genetics, Inc.（FLGT）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
Fulgent Genetics, Inc.的季度营收约是RE/MAX Holdings, Inc.的1.2倍（$83.3M vs $71.1M），RE/MAX Holdings, Inc.净利率更高（2.0% vs -28.1%，领先30.1%），Fulgent Genetics, Inc.同比增速更快（9.3% vs -1.8%），RE/MAX Holdings, Inc.自由现金流更多（$33.5M vs $-83.1M），过去两年Fulgent Genetics, Inc.的营收复合增速更高（13.7% vs -4.7%）
Fulgent Genetics是一家分子诊断技术企业，开发并提供覆盖携带者筛查、肿瘤基因检测、传染病检测、遗传性疾病分析的多元基因检测服务，主要客户为北美地区的医疗机构、药企、科研院所及公共卫生组织。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
FLGT vs RMAX — 直观对比
营收规模更大
FLGT
是对方的1.2倍
$71.1M
营收增速更快
FLGT
高出11.2%
-1.8%
净利率更高
RMAX
高出30.1%
-28.1%
自由现金流更多
RMAX
多$116.6M
$-83.1M
两年增速更快
FLGT
近两年复合增速
-4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $83.3M | $71.1M |
| 净利润 | $-23.4M | $1.4M |
| 毛利率 | 39.1% | — |
| 营业利润率 | -43.5% | 13.1% |
| 净利率 | -28.1% | 2.0% |
| 营收同比 | 9.3% | -1.8% |
| 净利润同比 | -297.7% | -75.2% |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FLGTRMAX
| Q4 25 | $83.3M | $71.1M | ||
| Q3 25 | $84.1M | $73.2M | ||
| Q2 25 | $81.8M | $72.8M | ||
| Q1 25 | $73.5M | $74.5M | ||
| Q4 24 | $76.2M | $72.5M | ||
| Q3 24 | $71.7M | $78.5M | ||
| Q2 24 | $71.0M | $78.5M | ||
| Q1 24 | $64.5M | $78.3M |
净利润FLGTRMAX
| Q4 25 | $-23.4M | $1.4M | ||
| Q3 25 | $-6.6M | $4.0M | ||
| Q2 25 | $-19.0M | $4.7M | ||
| Q1 25 | $-11.5M | $-2.0M | ||
| Q4 24 | $-5.9M | $5.8M | ||
| Q3 24 | $-14.6M | $966.0K | ||
| Q2 24 | $-8.7M | $3.7M | ||
| Q1 24 | $-13.5M | $-3.4M |
毛利率FLGTRMAX
| Q4 25 | 39.1% | — | ||
| Q3 25 | 42.2% | — | ||
| Q2 25 | 42.1% | — | ||
| Q1 25 | 38.6% | — | ||
| Q4 24 | 41.8% | — | ||
| Q3 24 | 37.3% | — | ||
| Q2 24 | 37.3% | — | ||
| Q1 24 | 34.3% | — |
营业利润率FLGTRMAX
| Q4 25 | -43.5% | 13.1% | ||
| Q3 25 | -18.3% | 25.0% | ||
| Q2 25 | -24.1% | 19.3% | ||
| Q1 25 | -26.9% | 7.2% | ||
| Q4 24 | -21.2% | 5.9% | ||
| Q3 24 | -23.8% | 19.4% | ||
| Q2 24 | -26.6% | 20.6% | ||
| Q1 24 | -33.8% | 5.8% |
净利率FLGTRMAX
| Q4 25 | -28.1% | 2.0% | ||
| Q3 25 | -7.9% | 5.4% | ||
| Q2 25 | -23.2% | 6.4% | ||
| Q1 25 | -15.7% | -2.6% | ||
| Q4 24 | -7.7% | 8.0% | ||
| Q3 24 | -20.4% | 1.2% | ||
| Q2 24 | -12.3% | 4.7% | ||
| Q1 24 | -20.9% | -4.3% |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $50.2M | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | $1.1B | $452.4M |
| 总资产 | $1.2B | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资FLGTRMAX
| Q4 25 | $50.2M | $118.7M | ||
| Q3 25 | $117.6M | $107.5M | ||
| Q2 25 | $87.9M | $94.3M | ||
| Q1 25 | $67.3M | $89.1M | ||
| Q4 24 | $55.1M | $96.6M | ||
| Q3 24 | $58.0M | $83.8M | ||
| Q2 24 | $65.1M | $66.1M | ||
| Q1 24 | $54.7M | $82.1M |
总债务FLGTRMAX
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
股东权益FLGTRMAX
| Q4 25 | $1.1B | $452.4M | ||
| Q3 25 | $1.1B | $448.1M | ||
| Q2 25 | $1.1B | $442.4M | ||
| Q1 25 | $1.1B | $433.5M | ||
| Q4 24 | $1.1B | $429.5M | ||
| Q3 24 | $1.1B | $423.1M | ||
| Q2 24 | $1.1B | $418.4M | ||
| Q1 24 | $1.1B | $412.0M |
总资产FLGTRMAX
| Q4 25 | $1.2B | $582.5M | ||
| Q3 25 | $1.2B | $582.2M | ||
| Q2 25 | $1.2B | $574.8M | ||
| Q1 25 | $1.2B | $571.4M | ||
| Q4 24 | $1.2B | $581.6M | ||
| Q3 24 | $1.2B | $578.6M | ||
| Q2 24 | $1.2B | $571.4M | ||
| Q1 24 | $1.2B | $566.7M |
负债/权益比FLGTRMAX
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-78.1M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $-83.1M | $33.5M |
| 自由现金流率自由现金流/营收 | -99.7% | 47.1% |
| 资本支出强度资本支出/营收 | 6.0% | 10.4% |
| 现金转化率经营现金流/净利润 | — | 28.39× |
| 过去12个月自由现金流最近4个季度 | $-124.2M | $56.8M |
8季度趋势，按日历期对齐
经营现金流FLGTRMAX
| Q4 25 | $-78.1M | $40.9M | ||
| Q3 25 | $11.1M | $17.7M | ||
| Q2 25 | $-30.2M | $4.6M | ||
| Q1 25 | $-4.4M | $5.7M | ||
| Q4 24 | $25.0M | $59.7M | ||
| Q3 24 | $-15.5M | $17.6M | ||
| Q2 24 | $4.3M | $15.9M | ||
| Q1 24 | $7.3M | $9.4M |
自由现金流FLGTRMAX
| Q4 25 | $-83.1M | $33.5M | ||
| Q3 25 | $5.1M | $16.4M | ||
| Q2 25 | $-37.0M | $2.9M | ||
| Q1 25 | $-9.1M | $4.0M | ||
| Q4 24 | $21.2M | $53.0M | ||
| Q3 24 | $-35.0M | $16.3M | ||
| Q2 24 | $-8.7M | $14.0M | ||
| Q1 24 | $3.2M | $6.8M |
自由现金流率FLGTRMAX
| Q4 25 | -99.7% | 47.1% | ||
| Q3 25 | 6.0% | 22.4% | ||
| Q2 25 | -45.2% | 4.0% | ||
| Q1 25 | -12.5% | 5.3% | ||
| Q4 24 | 27.9% | 73.2% | ||
| Q3 24 | -48.8% | 20.8% | ||
| Q2 24 | -12.2% | 17.8% | ||
| Q1 24 | 5.0% | 8.6% |
资本支出强度FLGTRMAX
| Q4 25 | 6.0% | 10.4% | ||
| Q3 25 | 7.2% | 1.8% | ||
| Q2 25 | 8.3% | 2.2% | ||
| Q1 25 | 6.4% | 2.3% | ||
| Q4 24 | 5.0% | 9.1% | ||
| Q3 24 | 27.2% | 1.7% | ||
| Q2 24 | 18.2% | 2.4% | ||
| Q1 24 | 6.3% | 3.3% |
现金转化率FLGTRMAX
| Q4 25 | — | 28.39× | ||
| Q3 25 | — | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | — | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FLGT
| Precision Diagnostics | $48.3M | 58% |
| Anatomic Pathology | $27.0M | 32% |
| Biopharma Services | $7.8M | 9% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
